Cybin Inc.(CYBN)Earnings, Financials & Key Ratios
CYBN•AMEX
$6.09
$304M mkt cap·Price updated Apr 24, 2026
AboutCybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.Show more
- Revenue$0
- EBITDA-$143M-81.6%
- Net Income-$113M-44.9%
- EPS (Diluted)-0.61+93.5%
- ROE-42.76%-0.8%
- ROIC-115.81%-3.6%
CYBN Key Insights
Cybin Inc. (CYBN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CYBN Price & Volume
Cybin Inc. (CYBN) stock price & volume — 10-year historical chart
Loading chart...
CYBN Growth Metrics
Cybin Inc. (CYBN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-56.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-921.18%
Return on Capital
10 Years-340.77%
5 Years-489.46%
3 Years-53.34%
Last Year-54.11%
CYBN Recent Earnings
Cybin Inc. (CYBN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (27%)
Q1 2026Latest
Feb 9, 2026EPS
$0.38
Est $0.53
+28.3%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$1.39
Est $0.74
-87.8%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$1.10
Est $0.51
-115.7%
Revenue
—
Q3 2025
Jun 30, 2025EPS
$1.02
Est $0.51
-100.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 9, 2026 | $0.38vs $0.53+28.3% | — |
| Q4 2025 | Nov 13, 2025 | $1.39vs $0.74-87.8% | — |
| Q3 2025 | Aug 13, 2025 | $1.10vs $0.51-115.7% | — |
| Q3 2025 | Jun 30, 2025 | $1.02vs $0.51-100.0% | — |
Based on last 12 quarters of dataView full earnings history →
CYBN Peer Comparison
Cybin Inc. (CYBN) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 895.52M | 9.32 | -3.03 | -335.93% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 ATAI | 961.75M | 4.00 | -4.30 | -1.91% | -51.09% | -96.43% | 0.21 | |
 SILO | 2.02M | 0.45 | -0.38 | -70.41% | -101.36% | |||
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 ENVB | 145.84K | 3.48 | -0.02 | -281.6% | ||||
 MAPS | 17.89M | 0.37 | 18.69 | -5.32% | 1.12% | 1.51% | 100% | 0.20 |
 INVA | 1.69B | 22.65 | 6.86 | 18.52% | 65.38% | 23.12% | 11.58% |
Compare CYBN vs Peers
Cybin Inc. (CYBN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CYBN Income Statement
Cybin Inc. (CYBN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jul'17 | Jul'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 864K | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | -100% | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 664K | 168K | 251K | 424K | 0 | 0 |
| COGS % of Revenue | - | - | - | 76.85% | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 200K▲ 0% | -168K▼ 184.0% | -251K▼ 49.4% | -424K▼ 68.9% | 0▲ 100.0% | 0▲ 0% |
| Gross Margin % | - | - | - | 23.15% | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | -184% | -49.4% | -68.92% | 100% | - |
| Operating Expenses | 127.22K | 80.52K | 1.94M | 30.72M | 63.84M | 51.52M | 78.84M | 143.15M | 147.45M |
| OpEx % of Revenue | - | - | - | 3556.02% | - | - | - | - | - |
| Selling, General & Admin | 127.22K | 80.52K | 1.63M | 26.52M | 46.25M | 25.37M | 46.47M | 88.24M | 84.33M |
| SG&A % of Revenue | - | - | - | 3069.1% | - | - | - | - | - |
| Research & Development | 0 | 0 | 321.6K | 3.3M | 17.59M | 26.14M | 32.36M | 54.91M | 63.12M |
| R&D % of Revenue | - | - | - | 381.94% | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -482K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -127K▲ 0% | -80.52K▲ 36.6% | -1.95M▼ 2326.7% | -31.04M▼ 1488.3% | -63.84M▼ 105.7% | -51.52M▲ 19.3% | -78.84M▼ 53.0% | -143.15M▼ 81.6% | -147.45M▲ 0% |
| Operating Margin % | - | - | - | -3592.01% | - | - | - | - | - |
| Operating Income Growth % | - | 36.6% | -2326.73% | -1488.28% | -105.7% | 19.3% | -53.03% | -81.58% | - |
| EBITDA | -127K | 80.62K | 0 | -30.99M | -63.67M | -51.28M | -78.58M | -142.67M | -147.08M |
| EBITDA Margin % | - | - | - | -3586.34% | - | - | - | - | - |
| EBITDA Growth % | - | 163.48% | -100% | - | -105.48% | 19.45% | -53.21% | -81.57% | -67.28% |
| D&A (Non-Cash Add-back) | 0 | 161.14K | 1.95M | 49K | 168K | 233K | 260K | 475K | 375K |
| EBIT | 0 | 0 | -1.95M | -32.21M | -63.84M | -51.52M | -78.84M | -143.15M | -147.45M |
| Net Interest Income | 0 | 0 | 0 | 50K | 0 | 603K | 619K | 8.29M | 4.19M |
| Interest Income | 0 | 0 | 0 | 60K | 241K | 603K | 619K | 8.29M | 7.1M |
| Interest Expense | 0 | 0 | 0 | 10K | 241K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4 | -20K | 9.6K | -1.7M | -3.79M | 4.03M | 756K | 30.01M | 24.53M |
| Pretax Income | -127K▲ 0% | -101K▲ 20.5% | -1.94M▼ 1824.8% | -32.22M▼ 1557.4% | -67.63M▼ 109.9% | -47.49M▲ 29.8% | -78.08M▼ 64.4% | -113.14M▼ 44.9% | -122.93M▲ 0% |
| Pretax Margin % | - | - | - | -3729.17% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -127K▲ 0% | -101K▲ 20.5% | -1.94M▼ 1824.8% | -32.22M▼ 1557.4% | -71.42M▼ 121.7% | -40.04M▲ 43.9% | -78.08M▼ 95.0% | -113.14M▼ 44.9% | -122.93M▲ 0% |
| Net Margin % | - | - | - | -3729.17% | - | - | - | - | - |
| Net Income Growth % | - | 20.47% | -1824.75% | -1557.41% | -121.68% | 43.94% | -95.02% | -44.9% | -56.81% |
| Net Income (Continuing) | -127K | -101K | -1.94M | -32.22M | -67.63M | -47.49M | -78.08M | -113.14M | -122.93M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -0.01▲ 21.7% | -0.04▼ 440.3% | -999999.00▼ 2570691416.7% | -0.43▲ 100.0% | -0.22▲ 48.8% | -9.41▼ 4177.3% | -0.61▲ 93.5% | -5.49▲ 0% |
| EPS Growth % | - | - | - | -99999900% | 100% | 48.84% | -4177.27% | 93.52% | -921.18% |
| EPS (Basic) | -0.01 | -0.01 | -0.05 | -999999.00 | -0.43 | -0.22 | -9.50 | -0.61 | - |
| Diluted Shares Outstanding | 13.89M | 13.89M | 49.98M | 10 | 167.29M | 185.43M | 185.43M | 185.43M | 22.4M |
| Basic Shares Outstanding | 13.89M | 13.89M | 40.5M | 10 | 167.29M | 185.43M | 185.43M | 185.43M | 22.4M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CYBN Balance Sheet
Cybin Inc. (CYBN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jul'17 | Jul'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 433.08K | 318.38K | 1.64M | 1.64M | 66.48M | 58.35M | 218.54M | 165.97M | 143.65M |
| Cash & Short-Term Investments | 432.81K | 314.32K | 1.54M | 1.54M | 64.03M | 53.64M | 208.99M | 135.02M | 118.69M |
| Cash Only | 432.81K | 314.32K | 1.54M | 1.54M | 64.03M | 53.64M | 208.99M | 135.02M | 118.69M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 74K | 1.33M | 2.1M | 3.05M | 0 | 5.88M | 4.11M |
| Days Sales Outstanding | - | - | - | 561.44 | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | -212K | 1.27M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | 0 | - | 1.85K | - | - | - |
| Other Current Assets | 263 | 4.06K | 0 | 0 | 1.34M | 1.77M | 2.18M | 2.91M | 1.69M |
| Total Non-Current Assets | 10K | 90K | 71K | 71K | 25.63M | 25.71M | 83.49M | 92.65M | 67.16M |
| Property, Plant & Equipment | 0 | 0 | 0 | 557K | 557K | 491K | 547K | 141K | 82K |
| Fixed Asset Turnover | - | - | - | 1.55x | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 23.37M | 23.37M | 22.89M | 47.48M | 51.49M | 36.9M |
| Intangible Assets | 0 | 0 | 0 | 1.7M | 1.7M | 2.08M | 35.47M | 41.02M | 30.18M |
| Long-Term Investments | 0 | 0 | 71K | 71K | 242K | 242K | 0 | 0 | 0 |
| Other Non-Current Assets | 10K | 90K | 0 | -25.63M | -242K | 0 | 0 | 0 | 0 |
| Total Assets | 443.08K▲ 0% | 408.38K▼ 7.8% | 1.71M▲ 319.0% | 1.71M▲ 0.0% | 92.11M▲ 5283.5% | 84.06M▼ 8.7% | 302.02M▲ 259.3% | 258.62M▼ 14.4% | 210.81M▲ 0% |
| Asset Turnover | - | - | - | 0.50x | - | - | - | - | 0.00x |
| Asset Growth % | - | -7.83% | 318.97% | 0% | 5283.52% | -8.74% | 259.28% | -14.37% | 410.47% |
| Total Current Liabilities | 150.29K | 13.65K | 263K | 263K | 4.9M | 7.91M | 10.1M | 21.42M | 14.55M |
| Accounts Payable | 0 | 0 | 263K | 2.79M | 5.26M | 5.66M | 9.8M | 21.42M | 0 |
| Days Payables Outstanding | - | - | - | 1.54K | 11.43K | 8.24K | 8.44K | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 150.29K | 13.65K | 0 | 2.11M | -362K | 2.25M | 291K | 0 | 14.55M |
| Current Ratio | 2.88x | 23.32x | 6.24x | 6.24x | 13.57x | 7.38x | 21.65x | 7.75x | 7.75x |
| Quick Ratio | 2.88x | 23.32x | 6.24x | 6.24x | 13.61x | 7.22x | 21.65x | 7.75x | 7.75x |
| Cash Conversion Cycle | - | - | - | -973.87 | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 1.09M | 1.09M | 5.26M | 0 | 0 | 44.5M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44.5M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 1.09M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 150.29K | 13.65K | 263K | 263K | 5.99M | 7.91M | 10.1M | 21.42M | 59.05M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 291K | 0 | 44.5M |
| Net Debt | -432.81K | -314.32K | -1.54M | -1.54M | -64.03M | -53.64M | -208.99M | -135.02M | -74.19M |
| Debt / Equity | - | - | - | - | - | - | 0.00x | - | 0.29x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.30x |
| Net Debt / EBITDA | - | -3.90x | - | - | - | - | - | - | 0.50x |
| Interest Coverage | - | - | - | -3103.50x | -264.89x | - | - | - | - |
| Total Equity | 292.78K▲ 0% | 394.73K▲ 34.8% | 1.45M▲ 266.8% | 1.45M▲ 0.0% | 86.12M▲ 5847.4% | 76.16M▼ 11.6% | 291.93M▲ 283.3% | 237.2M▼ 18.7% | 151.76M▲ 0% |
| Equity Growth % | - | 34.82% | 266.84% | 0% | 5847.38% | -11.57% | 283.33% | -18.75% | 460.74% |
| Book Value per Share | 0.02 | 0.03 | 0.03 | 144784.07 | 0.51 | 0.41 | 1.57 | 1.28 | 6.77 |
| Total Shareholders' Equity | 292.78K | 394.73K | 1.45M | 1.45M | 86.12M | 76.16M | 291.93M | 237.2M | 151.76M |
| Common Stock | 420K | 721.38K | 2.19M | 2.19M | 100.68M | 141.45M | 443.88M | 464.36M | 333.15M |
| Retained Earnings | -127.22K | -448.75K | -810K | -810K | -33.03M | -100.66M | -226.23M | -339.37M | -266.15M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 64 | 24K | 24K | -366K | 62.53M | -7.23M | 932K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CYBN Cash Flow Statement
Cybin Inc. (CYBN) cash flow — operating, investing & free cash flow history
| Line item | Jul'17 | Jul'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 2.81K | -83.78K | -1.39K | -19.03M | -19.03M | -45.21M | -68.91M | -101.3M | -101.3M |
| Operating CF Margin % | - | - | - | -2202.2% | - | - | - | - | - |
| Operating CF Growth % | - | -3077.43% | 98.35% | -1373889.02% | 0% | -137.59% | -52.43% | -47.01% | -140.21% |
| Net Income | -127.22K | -100.52K | -1.94K | -32.22M | -32.22M | -67.63M | -78.08M | -113.14M | -122.93M |
| Depreciation & Amortization | 0 | 0 | 0 | 49K | 49K | 168K | 424K | 475K | 375K |
| Stock-Based Compensation | 0 | 0 | 154 | 11.55M | 18.03M | 4.69M | 13.89M | 42.87M | 39.65M |
| Deferred Taxes | 0 | 0 | 0 | 898K | 898K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 20K | 631 | 1.96M | 1.96M | 4.01M | -111K | -21.71M | -20.32M |
| Working Capital Changes | 130.03K | -3.26K | -226 | -1.27M | -1.27M | 213K | -5.03M | -9.79M | -416K |
| Change in Receivables | 0 | 0 | -178 | -1.49M | -1.49M | -773K | -1.09M | -1.41M | -1.28M |
| Change in Inventory | 0 | 0 | 0 | -511K | -511K | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -10K | -35K | -170 | -1.19M | -1.19M | -770K | 6.92M | -1.97M | -1.95M |
| Capital Expenditures | -10K | -35K | 0 | -231K | -231K | -520K | -21 | -1.97M | -1.96M |
| CapEx % of Revenue | - | - | - | 26.74% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | -958K | -958K | 0 | 7.63M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -170 | -96 | 250K | -3.17K | -709.98K | 0 | 10K |
| Cash from Financing | 440K | 0 | 5.26K | 82.72M | 35.78M | 35.78M | 254.51M | 20.2M | 75.06M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -149K | -290K | 44.3M |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 440K | 0 | 5.26K | 6.49M | 35.78M | 362K | 56K | 0 | 149K |
| Net Change in Cash | 432.81K▲ 0% | -118.78K▼ 127.4% | 3.71K▲ 103.1% | 62.48M▲ 1684932.4% | 62.48M▲ 0.0% | -10.38M▼ 116.6% | 192.36M▲ 1952.3% | -73.97M▼ 138.5% | -23.48M▲ 0% |
| Free Cash Flow | -7.19K▲ 0% | -118.78K▼ 1553.0% | -1.39K▲ 98.8% | -19.26M▼ 1390369.3% | -19.26M▲ 0.0% | -45.73M▼ 137.4% | -69.62M▼ 52.2% | -103.27M▼ 48.3% | -105.59M▲ 0% |
| FCF Margin % | - | - | - | -2228.94% | - | - | - | - | - |
| FCF Growth % | - | -1553.01% | 98.83% | -1390570.13% | 0% | -137.44% | -52.25% | -48.33% | -22.35% |
| FCF per Share | -0.00 | -0.01 | -0.00 | -999999.00 | -0.12 | -0.25 | -0.38 | -0.56 | -0.56 |
| FCF Conversion (FCF/Net Income) | -0.02x | 0.83x | 0.00x | 0.59x | 0.27x | 1.13x | 0.88x | 0.90x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CYBN Key Ratios
Cybin Inc. (CYBN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -29.38% | -210.99% | -2225.14% | -163.13% | -49.35% | -42.43% | -42.76% | -81% |
| Return on Invested Capital (ROIC) | - | - | - | -435.36% | -173.24% | -111.83% | -115.81% | -115.81% |
| Gross Margin | - | - | 23.15% | - | - | - | - | - |
| Net Margin | - | - | -3729.17% | - | - | - | - | - |
| Debt / Equity | - | - | - | - | - | 0.00x | - | 0.29x |
| Interest Coverage | - | - | -3103.50x | -264.89x | - | - | - | - |
| FCF Conversion | 0.83x | 0.00x | 0.59x | 0.27x | 1.13x | 0.88x | 0.90x | 0.86x |
| Revenue Growth | - | - | - | -100% | - | - | - | - |
CYBN Frequently Asked Questions
Cybin Inc. (CYBN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cybin Inc. (CYBN) grew revenue by 0.0% over the past year. Growth has been modest.
Cybin Inc. (CYBN) reported a net loss of $122.9M for fiscal year 2025.
Dividend & Returns
Cybin Inc. (CYBN) has a return on equity (ROE) of -42.8%. Negative ROE indicates the company is unprofitable.
Cybin Inc. (CYBN) had negative free cash flow of $105.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More CYBN
Cybin Inc. (CYBN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates